BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22248856)

  • 1. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
    Tanabe K; Ishizaki J; Ando Y; Ito T; Nishimoto S
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1682-5. PubMed ID: 22248856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
    Tanabe K; Sugiura M; Ito T; Nishimoto S
    Bioorg Med Chem; 2012 Sep; 20(17):5164-8. PubMed ID: 22847019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
    Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
    Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
    Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs.
    Tanabe K; Mimasu Y; Eto A; Tachi Y; Sakakibara S; Mori M; Hatta H; Nishimoto S
    Bioorg Med Chem; 2003 Oct; 11(21):4551-6. PubMed ID: 14527551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
    Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
    Wu W; Borch RF
    Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
    Hirata N; Fujisawa Y; Tanabe K; Harada H; Hiraoka M; Nishimoto S
    Org Biomol Chem; 2009 Feb; 7(4):651-4. PubMed ID: 19194578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
    Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
    J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
    Rauko P; Novotny L; Mego M; Saiko P; Schott H; Szekeres T
    Neoplasma; 2007; 54(1):68-74. PubMed ID: 17203895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
    J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells.
    Saiko P; Horvath Z; Illmer C; Madlener S; Bauer W; Hoechtl T; Erlach N; Grusch M; Krupitza G; Mader RM; Jaeger W; Schott H; Agarwal RP; Fritzer-Szekeres M; Szekeres T
    Leuk Res; 2005 Jul; 29(7):785-91. PubMed ID: 15927674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity.
    Zhang Z; Hatta H; Tanabe K; Nishimoto S
    Pharm Res; 2005 Mar; 22(3):381-9. PubMed ID: 15835743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
    Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
    Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
    Cattaneo-Pangrazzi RM; Schott H; Wunderli-Allenspach H; Derighetti M; Schwendener RA
    Biochem Pharmacol; 2000 Dec; 60(12):1887-96. PubMed ID: 11108805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
    J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
    Maier S; Strasser S; Saiko P; Leisser C; Sasgary S; Grusch M; Madlener S; Bader Y; Hartmann J; Schott H; Mader RM; Szekeres T; Fritzer-Szekeres M; Krupitza G
    Apoptosis; 2006 Mar; 11(3):427-40. PubMed ID: 16538382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Azidobenzyl ferrocenylcarbamate as an anticancer prodrug activated under reductive conditions.
    Kinski E; Marzenell P; Hofer W; Hagen H; Raskatov JA; Knaup KX; Zolnhofer EM; Meyer K; Mokhir A
    J Inorg Biochem; 2016 Jul; 160():218-24. PubMed ID: 26970945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.